Harson Laboratories India Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 3.90 Cr
as on 24-10-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 21.00 Cr
as on 24-10-2024
- Revenue 8.26%
(FY 2023)
- Profit -105.85%
(FY 2023)
- Ebitda -67.79%
(FY 2023)
- Net Worth -1.62%
(FY 2023)
- Total Assets -1.30%
(FY 2023)
About Harson Laboratories India
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 3.90 Cr.
The company has closed loans amounting to ₹21.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Divyesh Vora, Bhavesh Vora, and Jayesh Vora serve as directors at the Company.
- CIN/LLPIN
U24100GJ2016PTC086086
- Company No.
086086
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Feb 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Harson Laboratories India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Divyesh Vora  | Director | 15-Feb-2016 | Current |
| Bhavesh Vora | Director | 15-Feb-2016 | Current |
| Jayesh Vora | Director | 15-Feb-2016 | Current |
Financial Performance of Harson Laboratories India.
Harson Laboratories India Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.26% increase. The company also saw a substantial fall in profitability, with a 105.85% decrease in profit. The company's net worth dipped by a decrease of 1.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Harson Laboratories India?
In 2023, Harson Laboratories India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Dec 2017 | ₹10.50 Cr | Satisfied |
Others Creation Date: 04 Dec 2017 | ₹10.50 Cr | Satisfied |
How Many Employees Work at Harson Laboratories India?
Harson Laboratories India has a workforce of 34 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Harson Laboratories India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Harson Laboratories India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
